Association between three VEGF polymorphisms and renal cell carcinoma susceptibility: a meta-analysis

  title={Association between three VEGF polymorphisms and renal cell carcinoma susceptibility: a meta-analysis},
  author={Qi Hou and Mao-yin Li and Wentao Huang and Fang Wei and J Peng and Ming-wu Lou and Jianguang Qiu},
  pages={50061 - 50070}
Several studies have reported an association between vascular endothelial growth factor (VEGF) gene polymorphisms rs2010963, rs3025039 and rs699947 and renal cell carcinoma (RCC). However, the results remain inconclusive and controversial. We therefore conducted a meta-analysis to evaluate this association. Electronic databases were searched for relevant case-control studies up to November 2016. RevMan 5.2 software and STATA version 12.0 were used for statistical analysis in our meta-analysis… 

Figures and Tables from this paper

A systematic review and meta-analyses of the relationship between glutathione S-transferase gene polymorphisms and renal cell carcinoma susceptibility

The dual GSTM1-GSTT 1-null genotype is detected to be associated with the onset of RCC in Asians, and there is an association between the GSTT1- null genotype and the clinical TNM stages in patients with R CC in the overall population.

Association of single nucleotide polymorphisms with renal cell carcinoma in Algerian population

The results indicate that ATM rs1800057 may have an effect on the risk of RCC, and suggest that ALDH9A1 was a protective factor against RCC in Algerian population.

Clinical Relevance of VEGFA (rs3025039) +936 C>T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes

In subjects with PMF, the VEGFA rs3025039 CT or TT genotypes are more common in those with JAK2V617F than in those without JAK 2V67F mutation and are associated with disease severity, poor prognosis, and risk of deep vein thrombosis.

Clinical Relevance of +936 C>T VEGFA and c.233C>T bFGF Polymorphisms in Chronic Lymphocytic Leukemia

Evidence is provided of the protective effect of the T/- rs3025039 VEGFA variant against B-CLL development and the association of CT/TT variants of the rs1449683 bFGF gene with genetic risk and an adverse survival.

Survival prediction of kidney renal papillary cell carcinoma by comprehensive LncRNA characterization

The prognosis index (PI) that consisted of 7 lncRNAs could predict the progression and outcomes of KIRP with accuracy and was considered an independent indicator for prognostication of KirP.

Hypoxia promoted renal cell carcinoma cell migration through regulating lncRNA-ENST00000574654.1.

It is suggested that hypoxia promoted RCC cell invasion through HIF-1α/lncRNA (ENST00000574654.1)/hnRNP/VEGF-A pathway and targeting this pathway could potentially improve therapeutic outcomes of renal cell carcinoma.

Haplotypes of single cancer driver genes and their local ancestry in a highly admixed long-lived population of Northeast Brazil

Analysis of SNP polymorphism in the present admixed population has a high potential to identify new ancestry-associated alleles and haplotypes that modify cancer susceptibility differentially in distinct human populations.

Expression of Livin and PlGF in human osteosarcoma is associated with tumor progression and clinical outcome

The results of the present study demonstrated that Livin and PlGF may participate in the pathogenesis of osteosarcoma and pharmacological inhibition of Livin or Pl GF may provide a novel strategy for osteosARcoma treatment.



Vascular endothelial growth factor gene polymorphisms and the risk of renal cell carcinoma: Evidence from eight case-control studies

A meta-analysis indicates that the +936C/T and -2578C/A polymorphisms of VEGF are associated with an increased risk for renal cell carcinoma.

Association between SNPs in vascular endothelial growth factor polymorphisms and risk of renal cell carcinoma: a case-control study.

Results showed that AA genotype of VEGF -2578C/A genetic variants is associated with increased risk of RCC.

Association of vascular endothelial growth factor polymorphisms with clinical outcome of renal cell carcinoma patients

Patients carrying VEGF−2578AA genotype and A allele significantly increased the risk of death from RCC, with the adjusted HRs of 2.23 (1.15–4.36) and 1.55 ( 1.11–2.17), respectively.

Variants in angiogenesis-related genes and the risk of clear cell renal cell carcinoma.

The results indicate that VEGFA rs2010963 and VEGFR3 rs448012 are associated with risk of ccRCC, and rs201 0963 is a functional SNP that may affectccRCC susceptibility by modulating endogenous VEG FA expression.

VEGF polymorphisms are associated with an increasing risk of developing renal cell carcinoma.

Predictive value of vascular endothelial growth factor polymorphisms on the clinical outcome of renal cell carcinoma patients

It is identified that the VEGF −2578C/A polymorphism may be associated with the prognosis of RCC patients, and may interact with the tumor stage and size.

Association between vascular growth factor gene-2578 C > A , + 1612 G > A polymorphism and the risk of renal cell carcinoma : a meta-analysis

It is indicated that V EGF -2578C>A polymorphism, but not VEGF +1612G>A pharmacological polymorphism was associated with the risk of RCC.

Investigating the association of vascular endothelial growth factor polymorphisms with breast cancer: a Moroccan case–control study

Significant associations of VEGF −1154A/G, −2578C/A and −460T/C polymorphisms with BC susceptibility in Moroccan individuals are indicated and can be useful as predisposing genetic markers for BC.

Predictive value of vascular endothelial growth factor polymorphisms on the risk of renal cell carcinomas: a case–control study

It is suggested that −2578C/A and +460T/C polymorphisms of VEGF modulate the risk of developing RCC in Chinese population.

Association of a single-nucleotide polymorphism in the promoter region of the VEGF gene with the risk of renal cell carcinoma.

This study shows that VEGF -2578 A-allele and A-carrier genotypes are associated with an increased risk of RCC and a screening test for this polymorphism may be recommended in conjunction with other established markers.